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We conducted a retrospective study of 99 patients 
with methicillin-suseptible Staphylococcus aureus 
catheter-related bacteremia in which vancomycin MIC was 
determined by Etest. High vancomycin MIC (>1.5 μg/mL) 
was the only independent risk factor for development of 
complicated bacteremia caused by methicillin-susceptible 
S. aureus (odds ratio 22.9, 95% conﬁ  dence interval 6.7–
78.1).
S
everal studies have established a relationship between 
high vancomycin MIC and a worse prognosis for 
patients with bacteremia caused by methicillin-resistant 
Staphylococcus aureus (MRSA) (1–5). However, to our 
knowledge, the role that a high vancomycin MIC could 
play in the clinical course of a patient with methicillin-
susceptible S. aureus (MSSA) bacteremia, has not been 
investigated, although a high vancomycin MIC has been 
also reported for strains of MSSA (6).
The Study
We retrospectively determined the MIC of vancomycin 
for the ﬁ  rst MSSA blood culture isolate from a cohort of 
99 adult patients with catheter-related bacteremia. These 
patients were consecutively evaluated from January 2002 
through December 2004 (mean follow-up 3 years) in 
University Hospital 12 de Octubre in Madrid, Spain, a 
1,000-bed university medical center.
We determined methicillin and vancomycin 
susceptibility by using broth microdilution according 
to Clinical Laboratory Standards Institute methods. 
Vancomycin MIC of was determined under blinded 
conditions by Etest in the ﬁ   rst isolate by using a 0.5 
McFarland inoculum streaked evenly with a swab onto 
Mueller-Hinton agar plates (7).
Complicated bacteremia was deﬁ   ned by one of 
the following events occurring after the ﬁ  rst  episode 
of bacteremia: 1) development of endocarditis, septic 
thrombophlebitis (deﬁ  ned by persistent MSSA bacteremia 
at least 72 hours after initiation of active antimicrobial 
drugs + documented thrombi), arthritis, spondylitis, as 
well as end-organ hematogenous spread of infection to 
other locations; or 2) infection involving vascular or 
osteoarticular prostheses (excluding intravascular catheter) 
not removed within 4 days. We also calculated the crude 
death rate in the ﬁ  rst 30 days after the ﬁ  rst positive blood 
culture (30-day mortality) and mortality rate attributable to 
S. aureus bacteremia (attributable death rate).
The Student unpaired t test was used to compare 
continuous variables, the Mann-Whitney U test to compare 
continuous variables with a nonnormal distribution, and the 
Fisher exact test to compare proportions. All statistical tests 
were 2-tailed and the threshold of statistical signiﬁ  cance 
was p<0.05. To analyze the risk factors for development 
of complicated bacteremia, we performed a multivariate 
forward stepwise logistic regression model including all 
the clinically relevant variables with a p value of <0.05 
and possible confounding factors with a p value of <0.1 
detected in the univariate analysis (SPSS software version 
15.0, SPSS, Chicago, IL, USA). 
All 99 MSSA strains were susceptible to vancomycin 
(MIC <2 μg/mL) by the broth microdilution method. Our data 
showed that, in 23/99 (23.2%) strains, MICs of vancomycin 
were >1.5 μg/mL by Etest (range 1.5–1.7 μg/mL).
Comparative data of patients with or without a high 
vancomycin MIC MSSA strain are shown in Table 1. The 
incidence of severe sepsis/septic shock was similar in both 
groups (21.7% vs. 14.5%; p = 0.69), but patients with high 
vancomycin MIC strains had complicated bacteremia more 
frequently (78.3% vs. 13.2%; p<0.0001). Attributable 
death rate was higher in patients with high vancomycin 
MIC strains with a difference that nearly achieves statistical 
signiﬁ  cance (17.4% vs. 3.9%; p = 0.08).
Comparative data between the 28 patients in whom 
complicated bacteremia developed and the remaining 
cohort are shown in Table 2. The percentage of isolates 
with vancomycin MIC >1.5 μg/mL was signiﬁ  cantly higher 
in patients with complicated bacteremia (18/28 [64.3%] vs. 
5/71 [7%]; p<0.0001). Initial treatment with glycopeptides 
was more frequent in patients in whom complicated 
bacteremia developed (82.1% vs 57.7%; p = 0.042). 
Among the 64 patients treated initially with glycopeptides, 
the rate of complicated bacteremia was signiﬁ  cantly higher 
in patients with high vancomycin MIC isolates (15/18 
[83.3%] vs. 8/46 [17.4%]; p<0.0001), as occurred in the 
25 patients treated initially with β-lactams, (3/5 [60%] vs. 
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DOI: 10.3201/eid1706.1010372/20 [10%]; p = 0.064). Vancomycin MIC >1.5 μg/mL 
was the only variable independently related to the risk for 
complicated bacteremia (OR 22.9, 95% conﬁ  dence interval 
6.7–78.1) in the multivariate analysis.
Conclusions
The aim of our study was to evaluate whether 
vancomycin MIC has any inﬂ   uence on the death rates 
and outcomes of patients with catheter-related MSSA 
bacteremia. We chose a MIC >1.5 μg/mL as interpretive 
criteria for diminished susceptibility on the basis of 
the reported treatment failure for infections caused by 
organisms who have exhibited this level of vancomycin 
MIC (5,8). A ﬁ  rst relevant ﬁ  nding of our study was the 
relatively high incidence of high vancomycin MIC among 
MSSA strains producing bacteremia (23.2%), a result 
similar to the percentage found for MRSA strains in our 
hospital (9,10).
Although a previous study found that vancomycin 
MICs for MSSA strains recovered from hemodialysis-
dependent patients with bacteremia who had been treated 
with vancomycin did not seem to be related to their clinical 
outcomes (11), recently published in vitro data suggest that 
isolates of S. aureus with high vancomycin MICs could 
be less susceptible to cloxacillin or daptomycin (6). Our 
data showed that patients with MSSA bacteremia caused 
by strains with high vancomycin MIC were not related to 
a higher rate of severe sepsis/septic shock development 
but were associated with a higher rate of complicated 
bacteremia. In fact, complicated bacteremia was related to 
a vancomycin MIC >1.5 μg/mL but not with other factors 
such as age, acquisition of infection, severity of underlying 
disease, or catheter management, which was conﬁ  rmed in 
the multivariate analysis.
 The initial treatment most frequently associated with 
complicated bacteremia, in patients with and without high 
vancomycin MIC, was the use of glycopeptides alone or 
followed by antistaphylococcal β-lactams. A possible 
explanation for this ﬁ  nding is that the ﬁ  rst hours of antibiotic 
treatment are crucial to avoid complications. Nevertheless, 
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Table 1. Differential characteristics of patients with bacteremia caused by MSSA strains with a MIC to vancomycin >1.5 μg/mL 
compared with <1.5 μg/mL by Etest, Hospital 12 de Octubre, Madrid, Spain, January 2002–December 2004* 
Characteristic MIC <1.5, n = 76 MIC >1.5, n = 23 p value
Mean age, y (SD) 63.55 (16.7)  62.9 (18.8)  0.87
M/F, % 69.7/30.3 56.5/43.5 0.36
Co-morbidity Charlson Index, mean (SD) 2.76 (2.7)  3.4 (3.7)  0.4
Previous valvular prosthesis  1 (1.3)  2 (8.7)  0.23
Other previous endovascular prosthesis 4 (5.3)  1 (4.3)  0.7
Previous osteoarticular prosthesis 3 (3.9)  0 0.79
Previous renal failure requiring hemodialysis 7 (9.2)  4 (17.4)  0.47
Type of IV catheter as the source of bacteremia
  Peripheral line  34 (44.7)  9 (39.1)  0.71
  Transitory central catheter  34 (44.7)  10 (43.5)  0.82
  Permanent central catheter  8 (10.6)  4 (17.4)  0.76
Vancomycin MIC of the first MSSA isolate, median (range) 1.2 (0.5–1.4)  1.5 (1.5–1.7)  <0.0001 
Initial treatment with glycopeptides 46 (60.5)  18 (78.3)  0.19
Initial treatment with antistaphylococcal E-lactams† 20 (26.3)  5 (21.7)  0.87
Initial treatment with non–E-lactam anti-staphylococcal agents‡ 7 (9.2)  0 0.29
Delay in initiation of active antibiotic treatment, d,§ mean (SD) 0.85 (1.06)  1.3 (1.6)  0.14
Duration of antibiotic treatment, d, mean (SD) 13.4 (8.24)  18.6 (12)  0.07
Prompt IV catheter removal¶ 62 (81.6)  17 (73.9)  0.45
Conservative IV catheter management# 4 (5.3)  2 (8.7)  0.32
Development of severe sepsis/septic shock 11 (14.5)  5 (21.7)  0.69
Complicated bacteremia  10 (13.2)  18 (78.3)  <0.0001 
  Septic thrombophlebitis  5 (6.6)  8 (34.9)  0.002 
 Endocarditis  3 (3.9)  4 (17.3)  0.08
  Osteoarticular  2 (2.6)  2 (8.7)  0.48
  Pulmonary emboli  0 2 (8.7)  0.08
 Other  02 ( 8 . 7 )  0 . 0 8
Crude 30-day death rate 8 (10.5)  6 (26.1)  0.13
Attributable death rate 3 (3.9)  4 (17.4)  0.083 
*Values are no. (%) except as indicated. MSSA, methicillin-susceptible Staphylococcus aureus; IV, intravenous. 
†Antistaphylococcal E-lactams refers to parenteral cloxacillin, cefazolin, amoxicillin-clavulanate, piperacillin-tazobactam, or imipenem/meropenem. 
‡Including non–E-lactam antibiotics with in vitro activity against MSSA (mostly levofloxacin, moxifloxacin or, clindamycin). 
§Delay since isolation of MSSA in blood cultures. 
¶Removal of catheter in the first 48 hours since isolation of MSSA in blood cultures. 
#Catheter kept at least 7 days since isolation of MSSA in blood cultures. Vancomycin MIC and MSSA Bacteremia 
in our opinion the greatest risk for complicated bacteremia 
related to strains of S. aureus with high vancomycin 
MIC should not only be attributed to the fact that these 
strains are more resistant to vancomycin because patients 
infected with strains with high vancomycin MIC that were 
initially treated with β-lactams also had a clear tendency 
to develop more complicated bacteremia. Nevertheless, 
the scarce number of patients who were treated initially 
with  β-lactams limit our results. We hypothesize that 
certain structural modiﬁ   cations might also occur in the 
cell wall of strains with high vancomycin MIC, including 
a thicker cell wall as it has been described in MRSA (12). 
Thickness of the cell wall should not only hinder the action 
of vancomycin, but also the arrival to the target (penicillin 
binding proteins of β-lactams). If this hypothesis is correct, 
a vancomycin MIC of 1.5–2 μg/mL in MSSA could be not 
only a marker of poor response to vancomycin but also 
a subrogate marker of suboptimal response to β-lactams 
and even pathogenicity, as has been recently suggested in 
MRSA isolates (13).
 Some limitations of this study deserve speciﬁ  c 
consideration. For most patients a treatment schedule 
including glycopeptides and β-lactams was used, so it is 
difﬁ  cult to analyze the role played by each antimicrobial 
drug. All our strains had a vancomycin MIC <2 μg/mL, 
so we do not know which would be the outcome of MSSA 
bacteremia caused by more resistant strains. We did not 
speciﬁ  cally test clonality of strains with high vancomycin 
MIC because we had previously demonstrated that 
MSSA strains isolated from patients with bacteremia at 
our institution (which coincided with most of the strains 
included in the present study) were polyclonal (14). 
Finally, some important variables such as the previous 
use of vancomycin or vancomycin serum levels were not 
included in the analysis. 
A high level of resistance to vancomycin is related 
with the development of complicated complicated 
bacteremia caused by MSSA, independent of the type of 
initial antibiotic treatment. Failure of glycopeptides does 
not appear to be the unique factor for the development of 
complicated bacteremia in patients with high vancomycin 
MIC isolates, and therefore intrinsic characteristics of these 
strains could also explain MSSA’s pathogenic role in the 
development of complicated bacteremia. 
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Table 2. Comparative analysis of 99 patients with complicated vs. noncomplicated MSSA bacteremia, Hospital 12 de Octubre, Madrid, 
Spain, January 2002–December 2004* 
Variable
Noncomplicated
MSSA, n = 71
Complicated
MSSA, n = 28 p value
Mean age, y (SD) 63.9 (17.4)  62 (16)  0.6
M/F, % 69/31 60.7/39.3  0.8
Co-morbidity Charlson Index, mean (SD) 2.92 (2.4)  2.93 (3.5)  0.9
Previous valvular prosthesis 1 (1.4)  2 (7.1)  0.39
Other previous endovascular prosthesis 4 (5.6)  1 (3.6)  0.9
Previous ostheoarticular prosthesis 2 (2.8)  1 (3.6)  0.8
Previous renal failure requiring hemodyalisis 8 (11.3)  3 (10.7)  0.8
Type of IV catheter as the source of bacteremia
  Peripheral line  32 (45.1)  11 (39.3)  0.7
  Transitory central catheter  30 (42.2)  14 (50)  0.8
  Permanent central catheter  9 (12.7)  3 (10.7)  0.9
Vancomycin MIC for the first MSSA isolate, median (range) 1.2 (0.5–1.7)  1.5 (1.0–1.7)  <0.0001 
Vancomycin MIC >1.5 μg/mL for the first MSSA isolate 5 (7)  18 (64.3)  <0.0001 
Initial treatment with glycopeptides 41 (57.7)  23 (82.1)  0.042 
Initial treatment with antistaphylococcal E-lactams† 20 (28.2)  5 (17.9)  0.42
Initial treatment with non–E-lactam antistaphylococcal agents‡ 7 (9.9)  0 0.19
Delay in initiation of active antibiotic treatment, d,§ mean (SD) 0.92 (1.3)  1.07 (1)  0.8
Delay >24 h at the start of effective antibiotics§ 28 (39.4)  14 (53.6)  0.2
Duration of antibiotic treatment, d, mean (SD) 12.77 (8)  19.39 (11.4)  0.002 
Prompt IV catheter removal¶ 58 (81.7)  21 (75)  0.65
Conservative IV catheter management# 5 (7)  1 (3.6)  0.8
Development of severe sepsis/septic shock  9 (12.7)  7 (25)  0.23
Days of follow-up, mean (SD) 502 (441)  462 (463)  0.77
Crude 30-day death rate 9 (12.7)  5 (17.9)  0.9
Attributable death rate 3 (4.2)  4 (14.3)  0.18
*Values are no. (%) except as indicated. MSSA, methicillin-susceptible Staphylococcus aureus; IV, intravenous.
†Antistaphylococcal E-lactams refer to parenteral cloxacillin, cefazolin, amoxicillin-clavulanate, piperacillin-tazobactam, or imipenem/meropenem. 
‡Including non–E-lactam antibiotics with in vitro activity against MSSA (mostly levofloxacin, moxifloxacin, or clindamycin). 
§Delay since isolation of MSSA in blood cultures. 
¶Removal of catheter in the first 48 h since isolation of MSSA in blood cultures. 
#Catheter kept at least 7 days since isolation of MSSA in blood cultures. This study was supported by Ministerio de Sanidad y 
Consumo, Instituto de Salud Carlos III–Fondo Europeo de 
Desarrollo Regional, Spanish Network for the Research in 
Infectious Diseases (REIPI RD06/0008), and Health Research 
Foundation (FIS PI08/81520).
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